Physician profile
Nikkeya Boyd
NPI 1831662469
$2,794.22
in general payments reported to CMS, 2019-2025
24 companies · $543 in 2025
The $543 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $417 · 2022: $509 · 2023: $866 · 2024: $460 · 2025: $543.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,868.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,868.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $767.59 | 2021-2025 | Wegovy |
| Sumitomo Pharma America, INC. | $274.33 | 2023-2024 | Myfembree |
| Gynesonics, INC. | $250.03 | 2023-2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Exeltis, USA INC. | $219.73 | 2023-2025 | Slynd, Twirla |
| Mayne Pharma Commercial LLC | $155.22 | 2021-2023 | |
| Hologic Sales and Service, LLC | $148.09 | 2023-2025 | Acessa Provu System, Thinprep 2000 Processor, Aptima |
| Abbvie INC. | $147.20 | 2021 | |
| Astellas Pharma US INC | $135.85 | 2025 | Veozah |
| Ibsa Pharma INC. | $104.16 | 2023 | Tirosint |
| Bayer Healthcare Pharmaceuticals INC. | $99.36 | 2022-2025 | |
| Aspira Women'S Health INC | $90.47 | 2024 | Ova1 |
| Organon LLC | $60.63 | 2021-2023 | Nexplanon |
| Lilly USA, LLC | $57.85 | 2024-2025 | Zepbound, Mounjaro |
| Merck Sharp & Dohme LLC | $46.00 | 2021-2023 | Pifeltro, Dificid, Delstrigo |
| Intra-Sana Laboratories | $38.40 | 2024 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $36.04 | 2025 | Cologuard Collection Kit |
| Boston Scientific Corporation | $34.38 | 2023-2024 | Upsylon |
| Baxter Healthcare | $21.86 | 2025 | Perclot |
| Myovant Sciences INC. | $20.40 | 2022 | |
| Therapeuticsmd, INC. | $19.23 | 2022 | |
| Scynexis, INC. | $18.46 | 2022 | |
| Gilead Sciences, INC. | $17.12 | 2025 | |
| Millicent US INC | $16.93 | 2024 | Intrarosa, Femring |
| Agile Therapeutics, INC. | $14.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nikkeya Boyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.